Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Global Research Management

Neither a doctor nor a teaching hospital

Research payments

$5,342,050

162 payments

Through program year 2025, Global Research Management is reported as receiving $5,342,050 in research payments, across 162 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,329,411 33
2024 Research $822,086 30
2023 Research $450,348 18
2022 Research $1,636,561 37
2021 Research $1,019,275 37
2020 Research $76,369 5
2019 Research $8,000 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $1,746,723 68 payments
  2. Glaukos Corporation $983,930 39 payments
  3. Bausch & Lomb Americas Inc. $755,474 5 payments
  4. Oyster Point Pharma, Inc. $643,267 14 payments
  5. Novartis Pharmaceuticals Corporation $630,680 5 payments
  6. Bausch Health US, LLC $302,638 21 payments
  7. AstraZeneca UK Limited $168,560 1 payment
  8. Dompe Farmaceutici S.p.A. $93,598 6 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $9,180 1 payment
  10. Mallinckrodt Enterprises LLC $8,000 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Multicenter, Double-Masked, Active-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness $755,474 5 payments
  2. A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis $643,267 14 payments
  3. Currently available treatments for presbyopia (old eye) include nonsurgical options (spectacles or contact lenses) and surgical options, however, each has its own risks and limitations. The purpose of this study is to evaluate how effective AGN-190584 is in treating presbyopia compared to vehicle (placebo). $557,829 5 payments
  4. A Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Efficacy of Ecf843 VS Vehicle in Subjects With Dry Eye Disease $416,630 3 payments
  5. AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension $355,485 24 payments
  6. Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Travoprost Ophthalmic Topical Cream in Subjects with Open-angle Glaucoma or Ocular Hypertension $335,825 13 payments
  7. A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of BID Dosing of AGN-190584 in Subjects with Presbyopia $241,063 7 payments
  8. A Phase 3, Multi-Center, Randomized, Double- Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction (GOBI) $223,940 7 payments
  9. A Phase 1 Randomized, Single blind,Placebo controlled,First in Human and Sequential Group Study to Assess Safety,Tolerability and Pharmacokinetics of AZD0186 Following Single Ascending Doses via Oral Administration $168,560 1 payment
  10. Phase 1x2F2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia $158,365 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record